Fusion Pharmaceuticals

OverviewSuggest Edit

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer. The Company is advancing [225Ac]-FPI-1434, its lead product candidate that combines the precision targeting of an antibody with the potency of alpha-particle emitting medical isotopes to specifically attack and eradicate cancer cells across multiple tumor types. It also operates Fast-Clear™, a linker technology platform that promotes the rapid excretion of medical isotopes that are not specifically bound to cancer cells.

TypePrivate
Founded2014
HQHamilton, CA
Websitefusionpharma.com

Latest Updates

Employees (est.) (Mar 2020)42
Job Openings3

Key People/Management at Fusion Pharmaceuticals

John Valliant

John Valliant

CEO
Eric Burak

Eric Burak

Chief Scientific Officer
Marc Schwabish

Marc Schwabish

SVP, Business Development and US Operations
Show more

Fusion Pharmaceuticals Office Locations

Fusion Pharmaceuticals has offices in Hamilton and Boston
Hamilton, CA (HQ)
270 Longwood Rd S
Boston, US
451 D St #930Boston
Show all (2)

Fusion Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2014

Fusion Pharmaceuticals total Funding

$170.9 m

Fusion Pharmaceuticals latest funding size

$19.92 m

Time since last funding

3 months ago

Fusion Pharmaceuticals investors

Fusion Pharmaceuticals's latest funding round in January 2020 was reported to be $19.9 m. In total, Fusion Pharmaceuticals has raised $170.9 m
Show all financial metrics

Fusion Pharmaceuticals Online and Social Media Presence

Embed Graph

Fusion Pharmaceuticals News and Updates

Precision oncology startup Fusion Pharmaceuticals raises $26 million CAD

Biopharmaceutical precision oncology startup Fusion Pharmaceuticals has received a commitment of up to $26 million CAD ($20 million USD) from the Canada Pension Plan...

Fusion Pharmaceuticals Blogs

Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. as Chief Medical Officer

Boston, MA & Hamilton, ON – March 23, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing... The post Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. as Chief Medical Officer appeared first on Fusion Pharma.

Fusion Pharmaceuticals Announces Appointment of Steven Gannon to Board of Directors

Boston, MA & Hamilton, ON – March 4, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing... The post Fusion Pharmaceuticals Announces Appointment of Steven Gannon to Board of Directors appeared first on Fusion Pharma.

Fusion Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D., to Board of Directors

Boston, MA & Hamilton, ON – February 6, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted... The post Fusion Pharmaceuticals Announces Appointment of Pablo J. Cagnoni, M.D., to Board of Directors appeared first on Fusion Pharma.

Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB)

Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation... The post Fusion Pharmaceuticals Announces Investment from Canada Pension Plan Investment Board (CPPIB) appeared first on Fusion Pharma.

Fusion Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing... The post Fusion Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference appeared first on Fusion Pharma.

A Phase I Study of [225Ac]-FPI-1434 Radioimmunotherapy in Patients with IGF-1R Expressing Solid Tumors

Background Type I insulin-like growth factor receptor (IGF-1R) is a transmembrane protein which is overexpressed in solid tumors including non–small... The post A Phase I Study of [225Ac]-FPI-1434 Radioimmunotherapy in Patients with IGF-1R Expressing Solid Tumors appeared first on Fusion Pharma.

Fusion Pharmaceuticals Frequently Asked Questions

  • When was Fusion Pharmaceuticals founded?

    Fusion Pharmaceuticals was founded in 2014.

  • Who are Fusion Pharmaceuticals key executives?

    Fusion Pharmaceuticals's key executives are John Valliant, Eric Burak and Marc Schwabish.

  • How many employees does Fusion Pharmaceuticals have?

    Fusion Pharmaceuticals has 42 employees.

  • Who are Fusion Pharmaceuticals competitors?

    Competitors of Fusion Pharmaceuticals include Century Therapeutics, Prelude Therapeutics and Actuate Therapeutics.

  • Where is Fusion Pharmaceuticals headquarters?

    Fusion Pharmaceuticals headquarters is located at 270 Longwood Rd S, Hamilton.

  • Where are Fusion Pharmaceuticals offices?

    Fusion Pharmaceuticals has offices in Hamilton and Boston.

  • How many offices does Fusion Pharmaceuticals have?

    Fusion Pharmaceuticals has 2 offices.